ELOVL3 and Alzheimer disease: In addition, some studies have revealed increased expression of skin barrier-associated genes, such as filaggrin, loricrin, claudins, and ELOVL3, and decreased expression of type 2 cytokines [26], which impair skin barrier function in lesional skin of AD patients treated with dupilumab [27,28].